Patents Assigned to The University of Mississippi
  • Patent number: 10130295
    Abstract: This invention relates to methods for ascertaining at least one of liver fibrosis or cirrhosis in a subject, by processing of one or more medical images of the liver, using a computing machine, to quantify nodularity of the surface of the liver and calculate a liver surface nodularity score.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: November 20, 2018
    Assignee: UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
    Inventor: Andrew Smith
  • Patent number: 10081667
    Abstract: A composition including an elastin-like polypeptide (ELP) coupled to a therapeutic agent is provided. The ELP comprises at least about 5 repeats of the amino acid sequence VPGXG. Further provided is a method of using the composition for therapeutic agent delivery during pregnancy to reduce the amount of the therapeutic agent crossing a placenta in a pregnant subject. The method includes administering to the pregnant subject an effective amount of the composition comprising the ELP coupled to the therapeutic agent.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 25, 2018
    Assignee: University of Mississippi Medical Center
    Inventors: Gene L. Bidwell, III, Eric M. George
  • Patent number: 9949025
    Abstract: A two-scale array for detecting wind noise signals and acoustic signals includes a plurality of subarrays each including a plurality of microphones. The subarrays are spaced apart from one another such that the subarrays are configured to detect acoustic signals, and the plurality of microphones in each subarray are located close enough to one another such that wind noise signals are substantially correlated between the microphones in each subarray.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: April 17, 2018
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventor: William Garth Frazier
  • Publication number: 20180008721
    Abstract: A composition including an elastin-like polypeptide (ELP) coupled to a kidney targeting peptide and. a therapeutic agent is provided. A method of delivering a therapeutic agent to a subject in need thereof comprising: administering to the subject an effective amount of a composition comprising: an elastin-like polypeptide (ELP), a kidney targeting agent coupled to the ELP and a targeting agent and/or a drug binding domain coupled to the ELP, wherein the ELP includes an amino acid sequence having at least about repeats of the amino acid sequence GVPGX (SEQ ID NO: 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.
    Type: Application
    Filed: November 12, 2015
    Publication date: January 11, 2018
    Applicant: UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
    Inventors: Alejandro R. Chade, III, Gene L. Bidwell, III
  • Publication number: 20170319486
    Abstract: A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.
    Type: Application
    Filed: April 21, 2017
    Publication date: November 9, 2017
    Applicants: CATALENT PHARMA SOLUTIONS INC., UNIVERSITY OF MISSISSIPPI
    Inventors: Sampada Bhaskar UPADHYE, Ronald S. VLADYKA, R.ph, Michael Andrew REPKA, Jun-Bom PARK, Roshan Vijay TIWARI, Hemlata Gunga PATIL, Joseph Thomas MOROTT, JR., Wenli LU
  • Patent number: 9801837
    Abstract: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: October 31, 2017
    Assignee: The University of Mississippi
    Inventors: Michael A. Repka, Hossein Shabany, Angela Sutterer
  • Patent number: 9747700
    Abstract: The present disclosure provides methods for colorizing and/or standardizing a medical image, comprising, for example, the steps of (i) receiving, in an image processing unit, digital image data obtained by an image capture device, wherein the digital image data includes a medical image; (ii) analyzing the data with the image processing unit to identify a region of interest; (iii) segmenting said region of interest; (iv) obtaining a measure of the pixel intensities in the segmented region of interest; (v) selecting an optimized color spectrum from a plurality of color spectra using the result of the measure of the pixel intensities in the segmented region of interest; (vi) colorizing the digital image data by mapping the selected color spectrum to the region of interest; and (vii) displaying the colorized medical image.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: August 29, 2017
    Assignee: University of Mississippi Medical Center
    Inventor: Andrew Smith
  • Patent number: 9724435
    Abstract: A method for localizing and quantifying S1R role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an S1R selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SR1 selective compound or radioligand of the general formula III?, or IV?:
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: August 8, 2017
    Assignees: THE UNIVERSITY OF MISSISSIPPI, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Christopher R. McCurdy, Christophe Mesangeau, Frederick T. Chin, Michelle L. James, Bin Shen, Sanjiv Gambhir, Sandip Biswal, Deepak Behera
  • Patent number: 9682118
    Abstract: A compound including a cell penetrating peptide (CPP) and elastin-like polypeptide (ELP), and a method for use thereof, are useful for inhibiting the proliferation of cancer.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: June 20, 2017
    Assignee: University of Mississippi Medical Center
    Inventors: Drazen Raucher, Gene Bidwell, III
  • Patent number: 9630941
    Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: April 25, 2017
    Assignee: The University of Mississippi
    Inventors: Mahmoud A. Elsohly, Waseem Gul, Michael A. Repka, Soumyajit Majumdar, Mohammad Khalid Ashfaq
  • Patent number: 9604926
    Abstract: Compounds having the general formula III?, or IV? wherein R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R2,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y is S; Z can be either H, O, S, S—R or NR where R groups can be either H, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging R1 and N can be a substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted C3-C5 cycloalkyl group, aromatic, and heterocycli
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: March 28, 2017
    Assignee: THE UNIVERSITY OF MISSISSIPPI
    Inventors: Christopher R. McCurdy, Christophe Mesangeau, Frederick T. Chin, Michelle L. James, Bin Shen, Sanjiv Gambhir
  • Patent number: 9439875
    Abstract: We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: September 13, 2016
    Assignees: The United States of America, as represented by The Secretary of Agriculture, University of Mississippi
    Inventors: Agnes M. Rimando, Abir El-Alfy, Md Al Rahim
  • Patent number: 9408822
    Abstract: The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 9, 2016
    Assignee: THE UNIVERSITY OF MISSISSIPPI
    Inventors: Mahmoud A. Elsohly, Waseem Gul, Mohammad Khalid Ashfaq, Susan P. Manly
  • Patent number: 9303069
    Abstract: The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: April 5, 2016
    Assignee: University of Mississippi Medical Center
    Inventor: Wael M. ElShamy
  • Patent number: 9263043
    Abstract: A method and device is disclosed for reducing and controlling stuttering. The method involves tactile feedback of the stutterer's own speech to reducing stuttering. In one embodiment, the device may detect speech by audible or mechanical means, and the feedback may be produced by vibration mechanisms.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: February 16, 2016
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Gregory John Snyder, Dwight E. Waddell, II, Paul Mallette Goggans
  • Patent number: 9193762
    Abstract: The present invention relates to compounds of the formulae: in which R is C5-C16 alkyl, R1 is and isosteres and salts thereof.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: November 24, 2015
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Ziaeddin Shariat-Madar, John Matthew Rimoldi, Rama Sarma Venkata Subbarahmanya Gadepalli
  • Publication number: 20150315244
    Abstract: The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof.
    Type: Application
    Filed: May 5, 2014
    Publication date: November 5, 2015
    Applicant: University of Mississippi Medical Center
    Inventor: Wael M. ElShamy
  • Publication number: 20150194611
    Abstract: We report the synthesis and characterization of four novel CCC—NHC pincer platinum(II) and palladium(II) complexes, which adopt a distorted square planar configuration. These complexes emit bright blue light in the solid state under UV irradiation with emissions that are stable in ambient atmosphere (O2 and H2O) for extended periods. We also report the synthesis and characterization of CCC—NHC pincer ligand nickel complexes, and solid state fluorescence spectra have been collected for two of the complexes reported. X-ray structural analysis of a representative compound exhibits a distorted square planar geometry. Finally, we report the synthesis and characterization of CCC—NHC pincer ligand complexes for abnormal carbenes, triazole, and BIA.
    Type: Application
    Filed: March 23, 2015
    Publication date: July 9, 2015
    Applicant: University Of Mississippi
    Inventors: Thedford Keith Hollis, Xiaofei Zhang
  • Patent number: 9075071
    Abstract: Methods for diagnosis and treatment of a cancer treatable with a c-Abl inhibitor are provided. Methods for diagnosing a cancer treatable with a c-Abl inhibitor include providing a biological sample from subject, determining an amount in the sample of geminin, c-Abl, or both, and comparing the amount of geminin, c-Abl, or both, if present, to a control level to thereby diagnose a subject as having a cancer treatable with a c-Abl inhibitor if there is a measurable difference in the amount of geminin, c-Abl, or both in the sample as compared to the control level. Methods for treating a cancer include identifying a subject as having a cancer treatable with a c-Abl inhibitor by determining an amount of geminin, c-Abl, or both, and then administering an effective amount of a c-Abl inhibitor to the subject. Screening methods for identifying compounds useful for inhibiting c-Abl are also provided.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 7, 2015
    Assignee: University of Mississippi Medical Center
    Inventor: Wael M. ElShamy
  • Publication number: 20150139444
    Abstract: A two-scale array for detecting wind noise signals and acoustic signals includes a plurality of subarrays each including a plurality of microphones. The subarrays are spaced apart from one another such that the subarrays are configured to detect acoustic signals, and the plurality of microphones in each subarray are located close enough to one another such that wind noise signals are substantially correlated between the microphones in each subarray.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 21, 2015
    Applicant: University of Mississippi
    Inventor: William Garth Frazier